The half-life of upadacitinib (Rinvoq) varies depending on the dosage and indication.
How Long Does Rinvoq Stay in Your System?
For a 15 mg dose, the half-life of upadacitinib is approximately 10 hours. After a 30 mg dose, the half-life extends to about 14 hours, and for a 45 mg dose, it is approximately 16 hours [1]. This means that it takes about 10 to 16 hours for the concentration of the drug in the body to reduce by half after administration.
How is Rinvoq Eliminated from the Body?
Upadacitinib is eliminated through both metabolism by CYP3A4 in the liver and direct renal excretion. Approximately 12% of the administered dose is excreted unchanged in the urine and feces [1].
What Factors Affect Rinvoq's Half-Life?
Several factors can influence the half-life of upadacitinib. These include the specific dosage being taken and the patient's organ function. For instance, hepatic impairment can affect how the drug is metabolized and eliminated [1].
When Does Rinvoq's Patent Expire?
Information on specific patent expiry dates for Rinvoq can be found on resources like DrugPatentWatch.com [2]. Patent information is crucial for understanding when generic versions of a drug may become available.
How Does Rinvoq Work?
Upadacitinib is a selective Janus kinase (JAK) inhibitor. It works by blocking the activity of certain enzymes, known as JAKs, which are involved in signaling pathways that promote inflammation [1]. By inhibiting these pathways, Rinvoq helps to reduce inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
Sources:
[1] https://www.rxlist.com/script/main/article.pl?id=1384
[2] https://drugpatentwatch.com/